{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014365","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.018217+00:00","generated_at":"2026-06-15T01:01:15.023056+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa Q1 2023: cash $103.9M, no debt; Phase 2 trials initiated/expanded","bullets":["Ended Q1 2023 with $103.9M cash and cash equivalents, zero debt.","Operating expenses $7.1M (up 50% YoY); R&D $3.5M (+134%) on (Z)-endoxifen trials.","Initiated Phase 2 EVANGELINE and new I-SPY 2 arm for (Z)-endoxifen in ER+/HER2- breast cancer.","Full enrollment of Phase 2 KARISMA breast density study expected by end of 2023.","US patent granted for (Z)-endoxifen enteric capsule (No. 11,572,334)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014365","json":"https://secwatch.observer/filing/0001437749-23-014365.json","markdown":"https://secwatch.observer/filing/0001437749-23-014365.md","text":"https://secwatch.observer/filing/0001437749-23-014365.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/0001437749-23-014365-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/atos20230508_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T01:01:15.023056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a94d857b30029dd9bf85a1eb077ba181789b255d","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2023.","evidence_excerpt":"Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a current focus on breast cancer, today announces financial results for the fiscal quarter ended March 31, 2023, and provides an update on recent company developments.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923014365/0001437749-23-014365-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}